Grail is far ahead of other companies with 2,000 doctors willing to prescribe the $949 test. Most insurance plans don’t cover the cost. The tests are being marketed without endorsements from medical groups or a recommendation from U.S. health authorities. Review by the Food and Drug Administration isn’t required for this type of test.
The history of cancer screening has taught caution. In 2004, Japan halted mass screening of infants for a childhood cancer after studies found it didn’t save lives. Last year, a 16-year study of 200,000 women in the United Kingdom found regular screening for ovarian cancer didn’t make any difference in deaths.
The evidence is strongest for screening tests for cancers of the breast, cervix and colon. For some smokers, lung cancer screening is recommended. Dr. Tomasz Beer of Oregon Health & Science University in Portland led the company-sponsored study that Joyce Ares joined in 2020. After a miserable winter of chemotherapy and radiation, doctors told her the treatment was a success.
Grail continues to update its test as it learns from these studies, and is sponsoring a trial with Britain’s National Health Service in 140,000 people to see if the blood test can reduce the number of cancers caught in late stages. Cancer treatments can have long-term side effects, he said,"and we don’t know how fast the tumor would have grown.” Treatment for Hodgkin lymphoma is so effective that delaying therapy until she felt symptoms might have achieved the same happy outcome.
Who wrote this headline
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: sciam - 🏆 300. / 63 Read more »